Types of Physical Activity in Nonalcoholic Fatty Liver Disease and All-Cause and Cardiovascular Mortality.

NHANES death exercise hepatic steatosis lifestyle modification

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
28 Feb 2023
Historique:
received: 31 01 2023
revised: 24 02 2023
accepted: 27 02 2023
entrez: 11 3 2023
pubmed: 12 3 2023
medline: 12 3 2023
Statut: epublish

Résumé

The impact of different types of physical activity (PA) on mortality in the context of nonalcoholic fatty liver disease (NAFLD) is not clearly defined and was investigated. This prospective study was performed using the 2007-2014 US National Health and Nutrition Examination Survey with mortality follow-up through 2019. Over a median follow-up of 8.6 years, leisure-time and transportation-related PA that fulfilled the criteria outlined in the PA guidelines (≥150 min/week) in NAFLD were associated with a risk reduction in all-cause mortality (hazard ratio [HR]: 0.76, 95% confidence interval [CI]: 0.59-0.98 for leisure-time PA; HR: 0.62, 95% CI: 0.45-0.86 for transportation-related PA). Leisure-time and transportation-related PA in NAFLD were inversely associated with all-cause mortality in a dose-dependent manner (

Identifiants

pubmed: 36902707
pii: jcm12051923
doi: 10.3390/jcm12051923
pmc: PMC10004264
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Int J Cancer. 2016 Feb 15;138(4):818-32
pubmed: 26317834
Hepatol Int. 2019 Mar;13(2):205-213
pubmed: 30694445
Complement Ther Med. 2019 Jun;44:9-13
pubmed: 31126580
Clin Gastroenterol Hepatol. 2022 Jun;20(6):e1438-e1455
pubmed: 34214678
Diabetes Care. 2019 Jul;42(7):1241-1247
pubmed: 31221695
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
Prog Cardiovasc Dis. 2019 Mar - Apr;62(2):127-134
pubmed: 30796942
Aliment Pharmacol Ther. 2015 Jan;41(1):65-76
pubmed: 25376360
Aliment Pharmacol Ther. 2022 Sep;56(6):942-956
pubmed: 35880713
JAMA. 2011 Jun 15;305(23):2448-55
pubmed: 21673296
J Hepatol. 2017 Oct;67(4):829-846
pubmed: 28545937
Hepatology. 2008 Dec;48(6):1791-8
pubmed: 18972405
JAMA. 2018 Nov 20;320(19):2020-2028
pubmed: 30418471
J Natl Cancer Inst. 2019 Nov 1;111(11):1142-1151
pubmed: 31168582
Hepatology. 2020 Nov;72(5):1556-1568
pubmed: 32012316
Clin Gastroenterol Hepatol. 2021 Jun;19(6):1240-1247.e5
pubmed: 32683103
Hepatology. 2019 Aug;70(2):511-521
pubmed: 30125379
J Hepatol. 2016 Jun;64(6):1388-402
pubmed: 27062661
Liver Int. 2015 Mar;35(3):944-52
pubmed: 24684289
Am J Gastroenterol. 2011 Mar;106(3):460-8; quiz 469
pubmed: 21206486
Liver Int. 2017 Jun;37(6):919-926
pubmed: 27917585
Aliment Pharmacol Ther. 2018 Nov;48(9):1003-1016
pubmed: 30295948
Dig Liver Dis. 2010 Jul;42(7):503-8
pubmed: 19766548
Hepatology. 2002 Feb;35(2):367-72
pubmed: 11826410
Am J Gastroenterol. 2014 Sep;109(9):1404-14
pubmed: 24957156

Auteurs

Donghee Kim (D)

Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305, USA.

Karn Wijarnpreecha (K)

Division of Gastroenterology and Hepatology, Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ 85004, USA.
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Banner University Medical Center, Phoenix, AZ 85006, USA.

Brittany B Dennis (BB)

British Columbia Centre on Substance Use, University of British Columbia, Vancouver, BC V6Z 2A9, Canada.

George Cholankeril (G)

Liver Center, Division of Abdominal Transplantation, Michael E. DeBakey Department of General Surgery, Baylor College of Medicine, Houston, TX 77030, USA.
Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.

Aijaz Ahmed (A)

Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305, USA.

Classifications MeSH